An FDA advisory committee discussed Sydnexis data on the company’s atropine-based approach to pediatric myopia control and did not shift decisively in favor of approval despite widespread clinical use of atropine. The panel instead leaned toward requiring additional evidence to establish meaningful benefit in children. Clinicians’ support for approval did not translate into consensus on what constitutes benefit strong enough for regulatory action, according to the coverage. The decision keeps attention on endpoint selection and the evidentiary bar for pediatric myopia interventions. The debate illustrates a key tension in myopia medicine: real-world practice can use similar therapies, but FDA review still depends on trial-validated measures of both efficacy and clinically relevant outcomes. The next step cited by the panel direction is another trial aimed at clarifying benefit magnitude rather than relying on existing datasets.